BIOVERSYS AG

Their core work

BioVersys is a Basel-based biotech SME developing small-molecule therapeutics against drug-resistant bacterial infections, with a strong focus on tuberculosis and antimicrobial resistance (AMR). They specialize in transcriptional modulation — designing compounds that boost the efficacy of existing antibiotics by targeting bacterial gene regulation. Their flagship work involves advancing ethionamide-boosting compounds through clinical development (Phase II) in partnership with GlaxoSmithKline. They also contribute drug discovery capabilities (high-throughput screening, structural biology) to broader anti-infective consortia targeting mycobacterial diseases.

What they specialise in

How they've shifted over time

BioVersys entered H2020 in 2017 as a participant in Train2Target, contributing to a broad consortium effort on next-generation antibiotics. By 2019, they had sharpened their focus significantly — coordinating TRIC-TB, a large clinical-stage program on TB treatment, while simultaneously expanding into non-tubercular mycobacteria (RespiriNTM). The trajectory shows a company moving from early-stage antibiotic research participation toward leading clinical development programs in mycobacterial diseases specifically.

BioVersys is moving from lab-stage research partnerships toward leading clinical-phase programs in mycobacterial disease, making them an increasingly credible partner for translational anti-infective projects.

How they like to work

BioVersys operates as both a consortium leader and a specialist contributor. They coordinated their largest project (TRIC-TB, €6.9M) while participating as a focused partner in two others, suggesting they can drive programs when the science aligns with their core platform but are equally comfortable contributing specific capabilities (screening, structural biology) to broader efforts. With 27 unique partners across 10 countries from just 3 projects, they work in large, internationally diverse consortia typical of infectious disease drug development.

BioVersys has built a network of 27 partners across 10 countries through just 3 projects, reflecting the large consortium model common in anti-infective R&D. Their partnership with GlaxoSmithKline on TRIC-TB signals access to major pharma networks alongside academic and SME collaborators.

What sets them apart

BioVersys occupies a rare niche: a biotech SME with a proprietary platform for modulating bacterial transcriptional regulators, positioned at the intersection of basic science and clinical development. Their GlaxoSmithKline partnership on TRIC-TB and Basel location (Europe's pharma capital) give them credibility and industry connections that most academic-origin biotechs lack. For consortium builders, they bring both a validated drug discovery platform and the operational maturity to coordinate multi-million euro clinical programs.

Highlights from their portfolio

• TRIC-TB
  Their largest project (€6.9M) and coordinator role — a Phase II clinical program to improve TB treatment by boosting ethionamide with transcriptional modulators, in partnership with GSK.
• RespiriNTM
  Long-running project (2019-2027) targeting non-tubercular mycobacteria with first-in-human ambitions, showing BioVersys expanding beyond TB into broader mycobacterial disease.
• Train2Target
  MSCA training network for next-generation antibiotics — signals BioVersys' commitment to building the next wave of anti-infective researchers alongside their commercial pipeline.